FDA is formally reviewing BPC-157, TB-500, MOTS-c, Semax, and 3 other gray market peptides at its July 2026 advisory committee meeting. The wellness clinic industry is watching closely.
These 7 peptides have no USP monographs, no FDA-approved drug status, and no path to legal 503A compounding until FDA acts. Most were previously in a do-not-compound category. Removal from that list is NOT a green light.
Across all 7 substances, FDA’s background documents flag the same problems: weak chemical characterization, no modern human clinical trials, unresolved immunogenicity risk, and manufacturing quality that is largely undocumented.
TB-500 is WADA-prohibited. MOTS-c is WADA-prohibited. Semax is approved in Russia under a different standard. BPC-157 is being reviewed for ulcerative colitis, which already has multiple approved therapies. The evidentiary bar is high.
Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more.
